Islanders are being encouraged to reuse and recycle pumpkins after Halloween.
Guernsey Waste said a “scary amount” of waste was produced at the end of October every year.
It said the pieces of flesh removed when carving pumpkins could be used in recipes such as pumpkin lasagne, spicy pumpkin soup and autumnal pumpkin tart.
The company said the more fibrous flesh from around the seeds could be home composted or put into the food waste caddy, along with the carved pumpkin.
Waste minimisation and sustainability officer Douglas Button said islanders bought thousands of pumpkins each year to carve or for decoration.
But h said the “best – and tastiest- parts of the pumpkin” were often forgotten and ended up being thrown away.
Islanders are also being asked to think about the number of single-use plastics they consume during Halloween, from sweet wrappers to costume items.
Mr Button said decorations and costumes could be reused in following years which also helped to save money.
He added: “Through a few small steps, people can have fun at Halloween while limiting any negative impacts on the environment.
“It’s all about trying to reduce, reuse and recycle as much as we can.”
Following yesterday’s regional GDP data, today brings the release of Poland’s October inflation figures, as always, the first inflation print from the CEE region. Our economists expect a slight increase from 2.9% to 3.0% YoY, in line with market expectations, while core inflation should remain unchanged at 3.2% YoY. Today’s figure could decide whether the National Bank of Poland cuts rates again next week. We believe that it will take a break, but a surprise to the downside could push the decision back towards a rate cut.
Yesterday’s GDP data in the Czech Republic and Hungary confirmed our bias and more divergence in economic performance in the region. While the Czech GDP surprised up, with a growth of 2.7% YoY, the Hungarian economy surprised down by 0.6% YoY, both roughly in line with our expectations. Although the market impact was almost invisible given the strong global story, in the longer term, this is clearly a story worth following.
Next week, we will see the meeting of the Czech National Bank, which will also publish a new forecast. Although headline inflation may give the impression that the central bank may be relaxed and may return to rate cuts one day, the economic data shows that the CNB needs to be cautious as we look ahead. The economy is growing at its fastest pace since the Covid rebound, and at the same time, wages are showing upside, which will keep core inflation higher. On the other hand, the Hungarian economy has confirmed its weak performance, and we believe that the market will push more dovish bets even though the NBH remains hawkish. This should gradually start to undermine the HUF in the medium term.
For now, the strong rate reaction in the CEE region to Wednesday’s hawkish Fed should offset the impact of a stronger US dollar, and we expect EUR/HUF and EUR/CZK to stabilise at current levels, while PLN will follow inflation figures.
Industrial production decreased by 0.1% quarter-on-quarter in the third quarter, primarily due to reductions in output related to US tariffs. Transportation equipment and iron/steel output declined in September, likely due to the lingering effects of US tariffs. Still, the recent easing of tariff tensions in several countries should support Japan’s production rebound in the coming months. Semiconductor equipment sales rose for a second consecutive month, suggesting that strong global chip demand continued. Meanwhile, retail sales rebounded 0.3% MoM in September, but missed the market consensus of 0.8%.
Both IP and retail sales fell in Q3, indicating a GDP contraction for 3Q25. However, a rebound in September points to a gradual economic recovery in the current quarter.
The BoJ cited trade uncertainty as the reason for pausing rate hikes yesterday. However, today’s data indicates a possible economic recovery that could support future rate hikes.
Today’s data supports our view that the BoJ is likely to hike rates in December.
China’s decision to impose export controls on rare earths was a “mistake” and drew attention to Beijing’s ability to use them as a coercive tool, US Treasury Secretary Scott Bessent said in an interview published Saturday.
Westlake Chemical Partners (WLKP) reported a net profit margin of 4.8%, matching last year’s performance. Earnings have declined by 6.7% per year over the past five years and most recently slipped into negative growth. Revenue is forecast to grow at 7.7% per year, lagging behind the broader US market’s 10.3% pace. Shares currently trade at $18.86, notably below the fair value estimate of $49.88. While reported earnings are viewed as high quality, concerns about dividend sustainability, financial strength, and underwhelming growth expectations are shaping how investors interpret these results.
See our full analysis for Westlake Chemical Partners.
The next section puts these results in context by comparing the numbers against the widely followed narratives. This is where consensus may hold up, and where opinions might get tested.
Curious how numbers become stories that shape markets? Explore Community Narratives
NYSE:WLKP Earnings & Revenue History as at Nov 2025
Westlake Chemical Partners maintained a net profit margin of 4.8%, unchanged from last year, showing resilience despite challenging sector conditions.
Momentum comes from stable cash flows and secure distribution agreements, which attract investors looking for reliable income even as broader manufacturing and chemical demand fluctuates.
Consistent margins support the investment case for predictable distributions, supporting the view that the partnership’s structure shields it from some cyclical shocks.
Investors favor its reputation as a “safe haven” for yield within a volatile sector, prioritizing reliability over headline growth.
Earnings have declined by 6.7% per year over the last five years, with the most recent period seeing negative earnings growth, highlighting an area of continued weakness.
While long-term profit deterioration fuels caution, proponents point out that high-quality earnings and durable parent company relationships can mitigate downside risk.
The extended earnings slump is offset by above-average reliability in reported earnings quality, which bulls say is unusual during sector downturns.
Even in the face of falling earnings, guaranteed partnership income streams limit short-term cash flow shocks that typically worry income-seeking investors.
Shares at $18.86 remain well below the DCF fair value estimate of $49.88, and the price-to-earnings ratio is lower than both the chemicals industry average and peer group, underscoring a notable discount.
The considerable gap between price and fundamental value draws attention from investors searching for value, especially with sector volatility keeping more richly valued peers out of reach.
This valuation disconnect suggests a margin of safety for buyers, even as weaker financial positioning and tepid revenue forecasts discourage some.
A discounted multiple to both industry and peers strengthens the value thesis, provided income stability persists.
Don’t just look at this quarter; the real story is in the long-term trend. We’ve done an in-depth analysis on Westlake Chemical Partners’s growth and its valuation to see if today’s price is a bargain. Add the company to your watchlist or portfolio now so you don’t miss the next big move.
Westlake Chemical Partners continues to struggle with declining earnings growth, soft long-term performance, and questions around the sustainability of its dividends.
If a more reliable income stream is what you want, check out these 2008 dividend stocks with yields > 3% that have strong yields and a track record of sustainable payouts.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include WLKP.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Quaker Chemical (KWR) remains unprofitable, with losses having increased at a rate of 1.1% per year over the last five years. While revenue is forecast to grow at 4% annually, this pace trails the broader US market’s expected 10.3% growth. For investors, slow revenue forecasts and persistent losses keep attention on the gap between the current trading price of $138.89 and the estimated fair value of $255.48. Sentiment is likely to remain cautious until the path to profitability becomes more visible.
See our full analysis for Quaker Chemical.
Next, we will see how these headline figures stack up against the market’s prevailing narratives for Quaker Chemical, highlighting where the numbers reinforce sentiment and where they raise new questions.
See what the community is saying about Quaker Chemical
NYSE:KWR Earnings & Revenue History as at Nov 2025
Analysts see profit margins climbing from -0.4% now to a sizable 25.9% by 2028, a dramatic swing that is unusual for the sector and signals high earnings leverage if improvements materialize.
According to the analysts’ consensus view, much of this turnaround banks on major shifts in product mix and cost control:
They highlight that double-digit growth in advanced, sustainable chemistries, combined with bold cost-cutting aimed at $40 million in annualized savings, is projected to elevate recurring margins across fast-growing verticals like automation and energy storage.
Yet, the consensus narrative also notes ongoing exposure to margin pressure from cost inflation and end-market risk, which have led to goodwill impairments and regional profit volatility, especially outside Asia.
See why analysts think Quaker Chemical’s margin shift could upend expectations. Read the full Consensus Narrative. 📊 Read the full Quaker Chemical Consensus Narrative.
Quaker’s net leverage stands at 2.6x trailing EBITDA, reflecting the strain of recent acquisitions, interest expense, and direct restructuring charges on the company’s capital structure.
Analysts’ consensus view contends that elevated financial risk and restricted flexibility may curb strategic moves:
Significant new investments, such as plants in China and Thailand, could boost longer-term earnings but also limit room for buybacks, further acquisitions, or balance sheet repairs until profits recover.
Bears point to increased interest costs and restructuring outlays, warning these may hold back net income and free cash flow, especially if targeted cost savings do not materialize as planned.
With shares trading at $138.89 while DCF fair value is estimated at $255.48 and the analyst price target is 157.60, Quaker Chemical stands at a notable discount to both intrinsic and consensus valuation models.
Analysts’ consensus view points out that this apparent bargain reflects real tension:
On one hand, the discount may entice if future earnings growth and margin expansion deliver as forecasted, as these would justify a higher price-to-earnings multiple down the line.
However, critics stress that a premium price-to-sales ratio and lag behind industry growth suggest the company’s discounted trading level is warranted until there is visible progress towards profitability and stronger financial footing.
To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Quaker Chemical on Simply Wall St. Add the company to your watchlist or portfolio so you’ll be alerted when the story evolves.
Noticed something different in the figures above? Share your perspective and craft a unique narrative in just a few minutes. Do it your way.
A great starting point for your Quaker Chemical research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.
Quaker Chemical’s heavy debt load, restructuring costs, and lagging profit margins create real uncertainty about its financial strength and flexibility in the future.
If you want companies in stronger shape, check out solid balance sheet and fundamentals stocks screener (1984 results) where you’ll find businesses with healthier balance sheets and far less financial stress than what Quaker faces today.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include KWR.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Akastor (OB:AKAST) remains in a loss-making position, with no signs of a positive net profit margin or quality earnings over recent periods. While the company has managed to reduce losses at a rate of 57.7% per year over the last five years, revenue is projected to decline by 1.9% annually for the next three years, and profit growth is not expected to accelerate beyond the wider Norwegian market. The combination of ongoing unprofitability, anticipated revenue contraction, and a price-to-sales ratio of 8.8x, which is much higher than the industry and peer averages, puts pressure on the valuation. The current share price of NOK 11.12 stands well above the estimated fair value of NOK 1.3.
See our full analysis for Akastor.
Next, we will see how these headline numbers compare with the prevailing market narratives, and whether recent results reinforce or challenge the story investors are following.
See what the community is saying about Akastor
OB:AKAST Earnings & Revenue History as at Nov 2025
Forecasts point to a sharp average annual revenue decrease of 36.9% over the next three years, setting Akastor apart even in a tough industry environment.
According to the analysts’ consensus view, while strategic contracts and operational improvements—such as AKOFS Offshore’s new agreements—are cited as potential stabilizing forces, the aggressive revenue guidance signals analysts remain cautious about near-term recovery.
Bulls highlight recent offshore contracts and asset sales as long-range growth drivers, yet consensus anchors on imminent top-line pressure.
Dividends from asset sales and organic growth at HMH are flagged as positives, but only if macroeconomic headwinds and supply chain disruptions do not further undermine revenue stability.
See how the latest numbers stack up to the consensus view and weigh the full story in our deep-dive 📊 Read the full Akastor Consensus Narrative..
Even if Akastor’s profit margin matches the GB Energy Services industry average of 12.2% in three years, earnings are projected to settle at NOK 28.2 million, which is dramatically lower than today’s NOK 1.6 billion.
Analysts’ consensus narrative emphasizes that achieving durable profitability is a steep climb, not least because global trade friction and supply chain issues threaten net margins and any material earnings improvement.
Persistent loss-making status overshadows operational efficiencies. Forecasts do not expect Akastor to become profitable within the next three years.
Scenarios modeled show only a convergence to sector margins, rather than a structural leap, which limits the scope for upside surprises unless operational catalysts over-deliver.
Akastor’s price-to-sales ratio stands at 8.8x, which is well above both the Norwegian Energy Services average of 0.8x and peers at 0.9x. This raises questions about whether expectations are too optimistic relative to declining fundamentals.
The consensus view underlines that at the current share price of NOK 11.12, investors are paying a significant premium over DCF fair value at NOK 1.30. Analysts see a price target of 19.0 as achievable only with a PE ratio of 255.4x on future earnings.
Market participants see little margin of safety. The wide spread between DCF value and both market and analyst targets reflects uncertainty over whether performance can justify elevated multiples.
While sector momentum could help, Akastor’s own revenue and margin trajectory leave little room for upside without tangible progress on contracts or divestments.
To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Akastor on Simply Wall St. Add the company to your watchlist or portfolio so you’ll be alerted when the story evolves.
Interpret the figures your own way. Use your insights to build a fresh narrative in just a few minutes with Do it your way.
Akastor faces persistent losses, heavy revenue declines, and a price that remains well above fair value. This situation casts doubt on any near-term recovery or upside potential.
If high valuations and unpredictable outlooks make you skittish, check out these 832 undervalued stocks based on cash flows to discover stocks trading at more attractive prices with stronger downside protection.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include AKAST.OL.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Eli Lilly (LLY) delivered standout results, with earnings climbing at a 20% annual pace over the past five years and surging 120% in the last year alone. Net profit margins rose to 31% versus 20.5% a year ago. Looking ahead, earnings are forecast to grow at 19.3% per year, outpacing the broader US market’s 15.9% estimate. Despite a lofty Price-to-Earnings ratio of 42 times, which sits well above industry norms, the current share price of $862.86 still trails a discounted cash flow fair value of $1,226.48. This highlights the tension between rapid growth and premium valuation as investors digest the report.
See our full analysis for Eli Lilly.
The next section puts these headline numbers in context by measuring them against widely held market narratives. Some assumptions will be confirmed, while others may face tough questions.
See what the community is saying about Eli Lilly
NYSE:LLY Earnings & Revenue History as at Nov 2025
Robust volume and revenue growth from medicines like Mounjaro and Zepbound, supported by a global chronic disease surge and new manufacturing capacity, are fueling sustained sales expansion well above the US market’s 10.4% revenue growth average.
Analysts’ consensus view highlights strategic bets on obesity and diabetes as the engine for continued market share gains and larger addressable markets.
Rapid global launches and rising demand underpin analyst forecasts of revenue rising 18.7% annually for the next three years, compared to industry averages.
This medical trend aligns with the consensus expectation of earnings reaching $34.2 billion and profit margins climbing from 25.9% to 38.4% by 2028.
For the full community debate on whether these launches can sustain such momentum, check out the consensus narrative and see how analysts break down both the upside and challenges. 📊 Read the full Eli Lilly Consensus Narrative.
Forecasted profit margins are set to leap from 25.9% to 38.4% in the next three years, with new drug launches in neurodegenerative and specialty categories (such as Kisunla and donanemab) underpinning this expectation.
Analysts’ consensus view sees margin expansion as a function of innovation and market reach, but warns that heavy R&D investment and overconcentration in a few therapies could lead to volatility.
Notably, a deep late-stage clinical pipeline is expected to open up multibillion-dollar markets, but failures or delays would meaningfully dent these margin projections.
Strategic use of digital platforms (LillyDirect) is flagged as another profit lever, but reliance on pricing power leaves margins vulnerable to regulatory changes.
Eli Lilly’s Price-to-Earnings ratio of 42 times sits far above the US Pharmaceuticals industry average of 18.1 times. The $862.86 share price remains below both the analyst target of $919.33 and the DCF fair value of $1,226.48.
Analysts’ consensus view acknowledges investors are willing to pay a premium based on outsized growth and margin prospects, as long as the company can navigate future risks.
The current valuation gap reflects bullish long-term expectations, tempered by uncertainty over drug pricing regulation and reliance on a handful of high-revenue drugs.
Even at this elevated multiple, the projected earnings power and fair value estimates provide some cushion. However, the ongoing premium depends on Eli Lilly delivering on innovation and scale.
To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Eli Lilly on Simply Wall St. Add the company to your watchlist or portfolio so you’ll be alerted when the story evolves.
Think you have a unique take on these results? Bring your perspective to life and build your own narrative in just a few minutes. Do it your way
A great starting point for your Eli Lilly research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
Eli Lilly’s heavy dependence on a handful of high-growth drugs leaves it vulnerable to regulatory shifts and volatility if market conditions change.
If that concentration risk makes you wary, search for more predictable performance with companies in stable growth stocks screener (2103 results) offering reliable revenue and earnings across all market cycles.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include LLY.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Consumer inflation declined to 2.8% year-on-year in October from 2.9% YoY in September, creeping closer to the National Bank of Poland’s target of 2.5%. There were no major surprises with respect to gasoline and house energy prices, and both categories had a pro-inflationary impact on October’s CPI reading.
High frequency data suggested that this year food prices were relatively stable, and we expected only a slight increase, whereas seasonality was largely what drove food prices up last October. A flat reading for food prices (0.0% MoM) was surprisingly low this year. Still, the main surprise came from core inflation excluding food and energy prices. We don’t yet know the full CPI details, but we estimate that it dropped to around 3% YoY from 3.2% YoY in the last two months.
The flash October CPI may convince the Monetary Policy Council to consider yet another 25bp rate cut at the November meeting. Policymakers have cut rates at each policy sitting on the rates since July, but the Council still has room for further policy easing. The new macroeconomic projection may also provide rate setters with more confidence in a favourable inflation scenario for Poland over the medium term. Our baseline scenario had assumed that rates would remain unchanged in November, but the low October CPI reading puts the decision into a slightly different perspective.
Policymakers continue to stress upside risks to the mid-term inflation outlook, including expansionary fiscal policy, robust consumption growth, elevated wage dynamics and uncertainty about the impact of ETS2 on prices – but inflation is inevitably heading towards the central bank target of 2.5% and may even undershoot it temporarily. We think a 25bp rate cut in November is now more likely than a pause.
China’s official manufacturing purchasing managers’ index slowed to 49.0, down from 49.8. This marked a 6-month low, tying April for the lowest level of the year. It came in below expectations for a smaller moderation to 49.6.
The slowdown was seen across all the major subcategories. Production fell into contraction for the first time in 6 months, down to 49.7. This was the lowest level since May 2023. The new orders subindex also fell after two consecutive months of increases, down to 48.8, the lowest level since August 2024. New export orders contributed to this decline, falling to a 6-month low of 45.9. Employment remained in contraction for a 32nd consecutive month. Yet, it saw a relatively smaller downturn of just 0.2pp to 48.3.
We saw large, medium, and small-sized enterprises all sliding into contractionary territory for the first time since April. The trend of larger enterprises outperforming continued in the month.
The downturn in the PMI marks a poor start to the fourth quarter and may cause some concern, given that growth has been supported by external demand and industrial activity. On a brighter note, the PMI has been in contractionary territory since April, but this has not translated into weakness in hard activity data. Come next month’s PMI data, it will be interesting to see if the tariff reduction and extended trade truce with the US help support a recovery of new export orders.
